Uses
CDDO Imidozolide (CDDO-Im) is a synthetic triterpenoid CDDO-Im inhibits fatty acid synthase expression and has antiproliferative and proapoptotic effects in human liposarcoma cells. Studies show that CDDO-Im is highly active in suppressing cellular proliferation of human leukemia and breast cancer cell lines as well as being an effective therapeutic agent in the treatment of other types of cancers.
Biological Activity
CDDO-Im is a bifunctional CDDO analog th at enhances NRF2-mediated antioxidant and anti-inflammatory activity by forming not only KEAP1 covalent adducts (Michael adducts via cysteines, acyl adducts via lysines and tyrosines) in the same manner as CDDO and CDDO-Me, but also by covalently transacylating arginine and serine residues in GSTP and cross-linking them to adjacent cysteine residues. CDDO-Im is typically used in the range of 1-40 nM in cultures, 2-5.5 mg/kg via i.p. and 2.5 mg/kg via i.v. in vivo (mice and rats).
